HCC
MCID: HPT023
MIFTS: 92

Hepatocellular Carcinoma (HCC) malady

Categories: Genetic diseases, Rare diseases, Liver diseases, Cancer diseases, Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Hepatocellular Carcinoma

Aliases & Descriptions for Hepatocellular Carcinoma:

Name: Hepatocellular Carcinoma 54 38 12 56 66 13 52 14
Liver Cancer 12 66 41 14
Liver Neoplasm 12 29 14
Hepatoma 12 66 14
Hcc 12 56 66
Adult Primary Hepatocellular Carcinoma 12 69
Primary Malignant Neoplasm of Liver 12 69
Malignant Neoplasm of Liver 12 69
Hepatoblastoma, Somatic 54 13
Hepatocellular Cancer 66 29
Primary Liver Cancer 12 50
Liver Neoplasms 42 69
Hepatic Cancer 12 52
Hepatoblastoma 56 69
Malignant Neoplasm of Liver, Not Specified As Primary or Secondary 12
Epithelial Hepatic and Intrahepatic Bile Duct Neoplasm 12
Rare Tumor of Liver and Intrahepatic Biliary Tract 50
Hepatocellular Carcinoma, Childhood Type, Somatic 54
Non-Resectable Primary Hepatic Malignant Neoplasm 12
Liver and Intrahepatic Biliary Tract Carcinoma 69
Resectable Malignant Neoplasm of the Liver 12
Malignant Neoplasm of Liver Unspecified 12
Primary Malignant Neoplasm of Liver Nos 12
Resectable Malignant Neoplasm of Liver 12
Malignant Neoplasm of Liver, Primary 12
Hepatocellular Carcinoma, Somatic 54
Malignant Hepato-Biliary Neoplasm 12
Primary Malignant Liver Neoplasm 50
Malignant Hepatobiliary Neoplasm 69
Hepatocellular Cancer, Somatic 54
Primary Tumor of the Liver 50
Carcinoma, Hepatocellular 42
Malignant Tumor of Liver 12
Primary Cancer of Liver 50
Primary Liver Carcinoma 50
Liver Cell Carcinoma 66
Ca Liver - Primary 12
Neoplasm of Liver 12
Hepatic Neoplasm 12
Liver Carcinoma 69
Adult Hepatoma 12
Lcc 66

Characteristics:

Orphanet epidemiological data:

56
hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (United States),1-5/10000 (Europe); Age of onset: All ages; Age of death: adult;
hepatoblastoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe); Age of onset: Childhood,Infancy,Neonatal; Age of death: early childhood,infantile;

HPO:

32
hepatocellular carcinoma:
Inheritance autosomal dominant inheritance somatic mutation heterogeneous


Classifications:

Orphanet: 56  
Rare hepatic diseases


External Ids:

OMIM 54 114550
Disease Ontology 12 DOID:3571 DOID:684 DOID:916
ICD10 33 C22.0 C22.9
ICD9CM 35 155.0 155.2
MESH via Orphanet 43 D018197 D006528
UMLS via Orphanet 70 C0206624
ICD10 via Orphanet 34 C22.2 C22.0

Summaries for Hepatocellular Carcinoma

MedlinePlus : 41 your liver is the largest organ inside your body. it helps your body digest food, store energy, and remove poisons. primary liver cancer starts in the liver. metastatic liver cancer starts somewhere else and spreads to your liver. risk factors for primary liver cancer include having hepatitis b or c heavy alcohol use having cirrhosis, or scarring of the liver having hemochromatosis, an iron storage disease obesity and diabetes symptoms can include a lump or pain on the right side of your abdomen and yellowing of the skin. however, you may not have symptoms until the cancer is advanced. this makes it harder to treat. doctors use tests that examine the liver and the blood to diagnose liver cancer. treatment options include surgery, radiation, chemotherapy, or liver transplantation. nih: national cancer institute

MalaCards based summary : Hepatocellular Carcinoma, also known as liver cancer, is related to glycogen storage disease and colorectal cancer, and has symptoms including micronodular cirrhosis, subacute progressive viral hepatitis and hepatosplenomegaly. An important gene associated with Hepatocellular Carcinoma is AXIN1 (Axin 1), and among its related pathways/superpathways are ERK Signaling and Glioma. The drugs Feridex I.V. and Nexavar have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cellular

Disease Ontology : 12 A liver carcinoma that has material basis in undifferentiated hepatocytes.

OMIM : 54 Hepatocellular carcinoma is the major histologic type of malignant primary liver neoplasm. It is the fifth most common... (114550) more...

UniProtKB/Swiss-Prot : 66 Hepatocellular carcinoma: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.

Wikipedia : 71 Hepatocellular carcinoma (HCC), also called malignant hepatoma, is the most common type of liver... more...

Related Diseases for Hepatocellular Carcinoma

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 398)
id Related Disease Score Top Affiliating Genes
1 glycogen storage disease 31.0 AFP APC CTNNB1 MET MYC TP53
2 colorectal cancer 30.6 APC AXIN1 CASP8 CCND1 CTNNB1 IGF2R
3 peritoneal mesothelioma 30.2 CCND1 CTNNB1 MET MYC PIK3CA TP53
4 cystadenoma 29.8 CASP8 MYC TP53
5 childhood hepatocellular carcinoma 12.3
6 mixed fibrolamellar hepatocellular carcinoma 12.1
7 fibrolamellar carcinoma 12.0
8 adult hepatocellular carcinoma 12.0
9 aflatoxins-related hepatocellular carcinoma 11.8
10 ruijs-aalfs syndrome 11.7
11 tyrosinemia, type i 11.4
12 hepatitis c virus 11.4
13 liver sarcoma 11.3
14 hepatoid adenocarcinoma 11.2
15 pityriasis rotunda 11.2
16 lethal congenital contracture syndrome 11.2
17 hepatitis 11.0
18 lung large cell carcinoma 11.0
19 cholestasis, progressive familial intrahepatic 2 10.9
20 citrullinemia, adult-onset type ii 10.9
21 hepatocellular clear cell carcinoma 10.9
22 sclerosing hepatic carcinoma 10.9
23 hepatitis b 10.8
24 leukoencephalopathy, cerebral calcifications, and cysts 10.8
25 lethal congenital contracture syndrome 1 10.8
26 cerebroretinal microangiopathy with calcifications and cysts 10.8
27 cardiomyopathy, dilated, 1h 10.8 AFP APC AXIN1 CASP8 CCND1 CDKN3
28 hepatitis c 10.7
29 proctitis 10.7 AFP CCND1 CTNNB1 MET MYC PIK3CA
30 malignant pleural solitary fibrous tumor 10.6 AFP CCND1 CTNNB1 MYC TP53 VEGFA
31 trachea squamous cell carcinoma 10.6 CCND1 CTNNB1 MYC PIK3CA TP53 VEGFA
32 placenta praevia 10.6 CCND1 CTNNB1 MYC PIK3CA TP53 VEGFA
33 split-hand/foot malformation with long bone deficiency 1 10.6 CASP8 CCND1 CDKN3 CTNNB1 MET MYC
34 nail disorder, nonsyndromic congenital, 3, 10.6 CCND1 CTNNB1 MYC PIK3CA TP53 VEGFA
35 basal cell carcinoma 7 10.6 CASP8 CCND1 CTNNB1 MET MYC PIK3CA
36 bardet-biedl syndrome 10.6 CCND1 CTNNB1 MYC TP53 VEGFA
37 nevoid hypermelanosis, linear and whorled 10.6 CCND1 CTNNB1 MYC TP53 VEGFA
38 muscular dystrophy-dystroglycanopathy , type b, 2 10.6 APC CCND1 CTNNB1 MYC PIK3CA TP53
39 asperger syndrome 10.6 APC AXIN1 CCND1 CTNNB1 MYC TP53
40 glucose-6-phosphate translocase deficiency 10.6 MET MYC PIK3CA TP53 VEGFA
41 cleft palate cardiac defect ectrodactyly 10.6 CCND1 MET TP53 VEGFA
42 hemorrhagic proctocolitis 10.6 CCND1 CTNNB1 MYC PIK3CA
43 systemic lupus erythematosus with nephritis 2 10.6 APC CASP8 CCND1 CTNNB1 IGF2R MET
44 gastroesophageal junction adenocarcinoma 10.6 AFP CCND1 CTNNB1 TP53
45 malignant ovarian mixed epithelial neoplasm 10.6 AFP APC CTNNB1 HNF1A TP53
46 pearson syndrome 10.6 CCND1 CTNNB1 TP53 VEGFA
47 breast malignant phyllodes tumor 10.6 CCND1 CTNNB1 MET TP53
48 adult medulloblastoma 10.6 CCND1 MYC TP53 VEGFA
49 basal cell nevus syndrome 10.6 APC AXIN1 CASP8 CTNNB1 MET MYC
50 facial dermatosis 10.6 AFP CCND1 CTNNB1 TP53

Comorbidity relations with Hepatocellular Carcinoma via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Alcoholic Liver Cirrhosis Deficiency Anemia
Hepatic Encephalopathy Intrahepatic Gall Duct Cancer
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatocellular Carcinoma:



Diseases related to Hepatocellular Carcinoma

Symptoms & Phenotypes for Hepatocellular Carcinoma

Symptoms by clinical synopsis from OMIM:

114550

Clinical features from OMIM:

114550

Human phenotypes related to Hepatocellular Carcinoma:

32
id Description HPO Frequency HPO Source Accession
1 hepatocellular carcinoma 32 HP:0001402
2 micronodular cirrhosis 32 HP:0001413
3 subacute progressive viral hepatitis 32 HP:0006572

UMLS symptoms related to Hepatocellular Carcinoma:


hepatosplenomegaly, icterus, abdominal pain, fever, malaise, constipation, diarrhea, dyspepsia, heartburn, nausea and vomiting, gastrointestinal gas

GenomeRNAi Phenotypes related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.14 IGF2R
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.14 PEG10 IGF2R
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.14 CTNNB1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.14 CTNNB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.14 CCND1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-129 10.14 PEG10
7 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.14 APC
8 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.14 IGF2R CASP8 PEG10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.14 PEG10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.14 CCND1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.14 PEG10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.14 PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.14 PIK3CA CCND1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.14 CCND1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.14 PIK3CA
16 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.14 CASP8
17 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.14 APC PIK3CA CTNNB1 CCND1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.14 MYC
19 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.14 PIK3CA CASP8
20 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.14 APC
21 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.14 CTNNB1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.14 CCND1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-2 10.14 CASP8
24 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.14 APC
25 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.14 IGF2R
26 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.14 CCND1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.14 CCND1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.14 MYC
29 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.14 IGF2R MYC CASP8 CCND1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.14 APC
31 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.14 CASP8
32 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.14 PEG10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.14 CCND1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.14 PIK3CA
35 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.14 CTNNB1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.14 IGF2R PEG10 APC PIK3CA CTNNB1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.14 CTNNB1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.14 IGF2R MYC CTNNB1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.14 APC CTNNB1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.14 CTNNB1

MGI Mouse Phenotypes related to Hepatocellular Carcinoma:

44 (show all 24)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 CCND1 CTNNB1 HNF1A IGF2R MET MTUS1
2 growth/size/body region MP:0005378 10.46 APC AXIN1 CASP8 CCND1 CTNNB1 FGL1
3 behavior/neurological MP:0005386 10.42 IGF2R MET AFP APC AXIN1 CCND1
4 cardiovascular system MP:0005385 10.42 APC AXIN1 CASP8 CCND1 CTNNB1 IGF2R
5 endocrine/exocrine gland MP:0005379 10.41 VEGFA AFP APC CASP8 CCND1 CTNNB1
6 homeostasis/metabolism MP:0005376 10.39 FGL1 HNF1A IGF2R MET MYC PIK3CA
7 mortality/aging MP:0010768 10.38 AFP APC AXIN1 CASP8 CCND1 CTNNB1
8 embryo MP:0005380 10.32 CASP8 CTNNB1 IGF2R APC AXIN1 MET
9 digestive/alimentary MP:0005381 10.28 APC AXIN1 CCND1 CTNNB1 HNF1A MET
10 immune system MP:0005387 10.28 PIK3CA STARD13 TP53 VEGFA APC CASP8
11 craniofacial MP:0005382 10.24 APC AXIN1 CCND1 CTNNB1 IGF2R MET
12 liver/biliary system MP:0005370 10.24 AFP APC CASP8 CTNNB1 FGL1 HNF1A
13 neoplasm MP:0002006 10.21 AFP APC CASP8 CCND1 CTNNB1 MET
14 integument MP:0010771 10.18 APC CASP8 CCND1 CTNNB1 HNF1A MYC
15 adipose tissue MP:0005375 10.16 APC FGL1 HNF1A MYC PIK3CA STARD13
16 nervous system MP:0003631 10.14 APC AXIN1 CASP8 CCND1 CTNNB1 IGF2R
17 limbs/digits/tail MP:0005371 10.11 APC AXIN1 CTNNB1 IGF2R MET MYC
18 muscle MP:0005369 10.11 APC CASP8 CTNNB1 HNF1A MET MYC
19 no phenotypic analysis MP:0003012 9.97 MYC APC CTNNB1 HNF1A MET PIK3CA
20 normal MP:0002873 9.97 APC AXIN1 CCND1 CTNNB1 IGF2R MET
21 renal/urinary system MP:0005367 9.96 APC AXIN1 CASP8 CTNNB1 HNF1A IGF2R
22 reproductive system MP:0005389 9.9 APC AXIN1 CCND1 CTNNB1 HNF1A IGF2R
23 respiratory system MP:0005388 9.56 AXIN1 CASP8 CCND1 CTNNB1 IGF2R MET
24 skeleton MP:0005390 9.36 APC AXIN1 CCND1 CTNNB1 FGL1 HNF1A

Drugs & Therapeutics for Hepatocellular Carcinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Feridex I.V. 17 FERUMOXIDES Advanced Magnetics Approved February 1996
2
Nexavar 17 46 SORAFENIB TOSYLATE Bayer/Onyx Approved December 2005

Drugs for Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 929)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 142217-69-4 153941
2
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
3
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2 198153-51-4 5360545
4
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
5
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
6
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
7
Ethiodized oil Approved Phase 4,Phase 2,Phase 3,Phase 1 8008-53-5
8
Sorafenib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 284461-73-0 216239 406563
9
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
10
Coal tar Approved Phase 4,Phase 3,Phase 2,Phase 1 8007-45-2
11
Telbivudine Approved, Investigational Phase 4,Phase 1,Phase 2 3424-98-4 159269
12
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2 525-66-6 4946
13
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142340-99-6 60871
14
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
15
Pravastatin Approved Phase 4,Phase 3,Phase 2 81093-37-0 54687
16
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2 128-13-2 31401
17
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
18
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2 99210-65-8, 215647-85-1
19
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
20 Tegafur Approved Phase 4,Phase 2 17902-23-7
21
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
22
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
23
Levoleucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 68538-85-2
24
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
25
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154361-50-9 60953
26
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
27
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1 2216-51-5 16666
28
Erythromycin Approved, Vet_approved Phase 4,Phase 2 114-07-8 12560
29
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
30
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
31
Tenofovir Approved, Investigational Phase 4,Phase 3 147127-20-6 464205
32
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 169590-42-5 2662
33 Parecoxib Approved Phase 4,Phase 3 198470-84-7
34
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
35
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
36
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 23214-92-8 31703
37
Epirubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 56420-45-2 41867
38
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1 15663-27-1 84093 441203 2767
39
Iron Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 7439-89-6 23925
40
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1 10540-29-1 2733526
41
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
42
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
43
lanreotide Approved Phase 4,Phase 2,Phase 3 108736-35-2
44
Somatostatin Approved Phase 4,Phase 3,Phase 2 38916-34-6, 51110-01-1 53481605
45
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
46
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3 1197-18-8 5526
47
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
48
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
49
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
50
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128794-94-5 5281078

Interventional clinical trials:

(show top 50) (show all 3484)
id Name Status NCT ID Phase
1 Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma Unknown status NCT01570166 Phase 4
2 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
3 Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00555334 Phase 4
4 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis Unknown status NCT01350206 Phase 4
5 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4
6 Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00557024 Phase 4
7 TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma Unknown status NCT00556803 Phase 4
8 Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm Unknown status NCT01351194 Phase 4
9 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
10 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4
11 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
12 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4
13 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
14 Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma Unknown status NCT00554905 Phase 4
15 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4
16 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4
17 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4
18 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4
19 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
20 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4
21 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4
22 Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding Unknown status NCT00567216 Phase 4
23 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4
24 Cholestatic Drug-induced Liver Injury Unknown status NCT01141322 Phase 4
25 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4
26 Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders. Unknown status NCT00179413 Phase 4
27 Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer Unknown status NCT01972503 Phase 4
28 Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4
29 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4
30 New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction Unknown status NCT01307878 Phase 4
31 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4
32 Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4
33 Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer Unknown status NCT00868569 Phase 4
34 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
35 Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer Unknown status NCT00874406 Phase 4
36 Avastin in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01972490 Phase 4
37 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
38 Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury Unknown status NCT01802996 Phase 4
39 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
40 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4
41 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
42 Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Unknown status NCT00313066 Phase 4
43 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease Unknown status NCT02010762 Phase 4
44 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4
45 Prophylaxis of CHB Patients With Malignant Tumor Receiving Chemotherapy Unknown status NCT02081469 Phase 4
46 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4
47 Role of Parecoxib Sodium for Postoperative Pain Management in Open Hepatectomy Unknown status NCT02204878 Phase 4
48 Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis Completed NCT01575574 Phase 4
49 Drug-eluting Bead in Hepatocellular Carcinoma Completed NCT01332669 Phase 4
50 Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus Completed NCT01600196 Phase 4

Search NIH Clinical Center for Hepatocellular Carcinoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatocellular Carcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: carcinoma, hepatocellular

Genetic Tests for Hepatocellular Carcinoma

Genetic tests related to Hepatocellular Carcinoma:

id Genetic test Affiliating Genes
1 Hepatocellular Carcinoma 29
2 Neoplasm of the Liver 29

Anatomical Context for Hepatocellular Carcinoma

MalaCards organs/tissues related to Hepatocellular Carcinoma:

39
Liver, Endothelial, T Cells, Testes, Skin, Colon, Thyroid

Publications for Hepatocellular Carcinoma

Articles related to Hepatocellular Carcinoma:

(show top 50) (show all 9218)
id Title Authors Year
1
WNT1 Gene from WNT Signaling Pathway Is a Direct Target of miR-122 in Hepatocellular Carcinoma. ( 27687586 )
2017
2
Thymidine phosphorylase promotes metastasis and serves as a marker of poor prognosis in hepatocellular carcinoma. ( 28530649 )
2017
3
Oncogenic function of Plac1 on the proliferation and metastasis in hepatocellular carcinoma cells. ( 27878289 )
2017
4
NEK2 serves as a prognostic biomarker for hepatocellular carcinoma. ( 28101574 )
2017
5
Overexpression of NAD(P)H: Quinone Oxidoreductase 1 Inhibits Hepatocellular Carcinoma Cell Proliferation and Induced Apoptosis by Activating AMPK/PGC-1I+ Pathway. ( 28191864 )
2017
6
Histological Subtypes of Hepatocellular Carcinoma Are Related To Gene Mutations and Molecular Tumour Classification. ( 28532995 )
2017
7
A different representation of natural T cells and natural killer cells between tumor-infiltrating and periphery lymphocytes in human hepatocellular carcinoma. ( 28529568 )
2017
8
Modification of p27 with O-linked N-acetylglucosamine regulates cell proliferation in hepatocellular carcinoma. ( 27175940 )
2017
9
Effect of Background Liver Cirrhosis on Outcomes of Hepatectomy for Hepatocellular Carcinoma. ( 28052155 )
2017
10
Diabetes mellitus increases the risk of intrahepatic recurrence of hepatocellular carcinoma after surgical resection. ( 28085178 )
2017
11
Integrin I^4 promotes cell invasion and epithelial-mesenchymal transition through the modulation of Slug expression in hepatocellular carcinoma. ( 28084395 )
2017
12
Transcriptional activation of PD-L1 by Sox2 contributes to the proliferation of hepatocellular carcinoma cells. ( 28339084 )
2017
13
Viral hepatitis status does not affect survival in patients with hepatocellular carcinoma. ( 28042245 )
2017
14
miR-195 inhibits cell proliferation via targeting AEG-1 in hepatocellular carcinoma. ( 28529562 )
2017
15
Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma. ( 28085184 )
2017
16
CKLF-Like MARVEL Transmembrane Domain-Containing Member 3 (CMTM3) Inhibits the Proliferation and Tumorigenisis in Hepatocellular Carcinoma Cells. ( 27629543 )
2017
17
Increased ERp57 Expression in HBV-Related Hepatocellular Carcinoma: Possible Correlation and Prognosis. ( 28373975 )
2017
18
High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the PI3K/AKT signaling pathway. ( 28347229 )
2017
19
Klf4 inhibits tumor growth and metastasis by targeting microRNA-31 in human hepatocellular carcinoma. ( 27909734 )
2017
20
Incidence of Occult Intrahepatic Metastasis in Hepatocellular Carcinoma Treated With Transplantation Corresponds to Early Recurrence Rates After Partial Hepatectomy. ( 28085695 )
2017
21
Long non-coding RNA XIST promotes cell growth by regulating miR-139-5p/PDK1/AKT axis in hepatocellular carcinoma. ( 28231734 )
2017
22
Isorhynchophylline, a Potent Plant Alkaloid, Induces Apoptotic and Anti-Metastatic Effects in Human Hepatocellular Carcinoma Cells through the Modulation of Diverse Cell Signaling Cascades. ( 28534824 )
2017
23
Association of Inflammasome Components in Background Liver with Poor Prognosis After Curatively-resected Hepatocellular Carcinoma. ( 28011505 )
2017
24
B-cell lymphoma 2 inhibitor ABT-737 induces Beclin1- and reactive oxygen species-dependent autophagy in Adriamycin-resistant human hepatocellular carcinoma cells. ( 28351336 )
2017
25
Hepatocellular carcinoma presenting with Budd-Chiari syndrome, right atrial thrombus and pulmonary emboli. ( 28372458 )
2017
26
Characterization of the GNMT-HectH9-PREX2 tripartite relationship in the pathogenesis of hepatocellular carcinoma. ( 28205209 )
2017
27
Effect of Age (over 75A Years) on Postoperative Complications and Survival in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma. ( 28083840 )
2017
28
Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma. ( 28079796 )
2017
29
Resin versus Glass Microspheres for Yttrium-90 Transarterial Radioembolization: Comparing Survival in Unresectable Hepatocellular Carcinoma using Pretreatment Partition Model Dosimetry. ( 28082436 )
2017
30
SIRT3 functions as a tumor suppressor in hepatocellular carcinoma. ( 28347248 )
2017
31
Meta-analysis of possible role of cadherin gene methylation in evolution and prognosis of hepatocellular carcinoma with a PRISMA guideline. ( 28422868 )
2017
32
MicroRNA-200a Suppresses Cell Invasion and Migration by Directly Targeting GAB1 in Hepatocellular Carcinoma. ( 28081727 )
2017
33
Synergisic effect of APRIL knockdown and Jiedu Xiaozheng Yin, a Chinese medicinal recipe, on the inhibition of hepatocellular carcinoma cell proliferation. ( 28035399 )
2017
34
Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma: Study of Midterm Doxorubicin Delivery in Resected Liver Specimens. ( 28532743 )
2017
35
Hepatocellular Carcinoma in Fanconi-Bickel Syndrome. ( 28382841 )
2017
36
Long non-coding RNA colon cancer-associated transcript 1 functions as a competing endogenous RNA to regulate cyclin-dependent kinase 1 expression by sponging miR-490-3p in hepatocellular carcinoma progression. ( 28381168 )
2017
37
MicroRNA-34c-3p promotes cell proliferation and invasion in hepatocellular carcinoma by regulation of NCKAP1 expression. ( 27704267 )
2017
38
The Significance of Glypican-3 Expression Profiling in the Tumor Cellular Origin Theoretical System for Hepatocellular Carcinoma Progression. ( 28087980 )
2017
39
Stratified aspartate aminotransferase-to-platelet ratio index accurately predicts survival in hepatocellular carcinoma patients undergoing curative liver resection. ( 28351330 )
2017
40
The Expression and Functional Significance of Runx2 in Hepatocellular Carcinoma: Its Role in Vasculogenic Mimicry and Epithelial-Mesenchymal Transition. ( 28264434 )
2017
41
A 4-Phenoxyphenol Derivative Exerts Inhibitory Effects on Human Hepatocellular Carcinoma Cells through Regulating Autophagy and Apoptosis Accompanied by Downregulating I+-Tubulin Expression. ( 28531143 )
2017
42
Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis. ( 28533669 )
2017
43
Targeting MUC1 and JNK by RNA interference and inhibitor inhibit the development of hepatocellular carcinoma. ( 28012230 )
2017
44
What is the optimal treatment of metastatic hepatocellular carcinoma after complete resection; case presentation of ovarian metastasis. ( 28534387 )
2017
45
CD147 as a Novel Prognostic Biomarker for Hepatocellular Carcinoma: A Meta-Analysis. ( 28386553 )
2017
46
Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma. ( 28533668 )
2017
47
Overexpression of RIP140 suppresses the malignant potential of hepatocellular carcinoma by inhibiting NFa89I_Ba89mediated alternative polarization of macrophages. ( 28393222 )
2017
48
Bioinformatics prediction and experimental validation of microRNA-20a targeting Cyclin D1 in hepatocellular carcinoma. ( 28378640 )
2017
49
Polyethylene glycol-poly(I/-benzyloxycarbonyl-l-lysine)-conjugated VEGF siRNA for antiangiogenic gene therapy in hepatocellular carcinoma. ( 28533682 )
2017
50
Human U Three Protein 14a Expression is Increased in Hepatocellular Carcinoma and Associated with Poor Prognosis. ( 28218222 )
2017